Service de Néphrologie-Dialyse-Transplantation, Université d'Angers, CHU Angers, Angers, France.
Service de Néphrologie, Centre Hospitalier du Mans, Le Mans, France.
Nephrol Dial Transplant. 2022 May 25;37(6):1078-1087. doi: 10.1093/ndt/gfab158.
Lymphopaenia is commonly observed in autoimmune diseases, where it has been associated with disease activity or prognosis. However, in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) only a few small-scale studies have been targeted towards this issue. Research has not yet focused on AAV with renal involvement (AAV-RI). Thus the aim of this study was to analyse the association between lymphocyte counts and outcomes in a large cohort of AAV-RI patients.
We used the Maine-Anjou AAV registry that retrospectively gathers data on consecutive patients affected by AAV in four French nephrology centres, recorded since January 2000. We analysed clinical, biological and histological data at diagnosis of AAV-RI. Risk factors for end-stage kidney disease (ESKD) were analysed. Event-free survival was also assessed.
Among the 145 patients included in the study, those with lymphopaenia at diagnosis had a lower renal function at baseline [estimated glomerular filtration rate (eGFR) 13 versus 26 mL/min; P = 0.002] and were more likely to require kidney replacement therapy (51% versus 25%; P = 0.003). Lymphopaenia was correlated with histological lesions and especially with the percentage of sclerotic glomeruli (P = 0.0027). ESKD-free survival was lower in lymphopaenic patients (P < 0.0001). In multivariate Cox analysis, lymphopaenia was an independent risk factor for ESKD [hazard ratio 4.47 (95% confidence interval 2.06-9.72), P < 0.001].
Lymphopaenia correlates with the severity of AAV glomerulonephritis at diagnosis and predicts poor renal outcome. In this view, lymphopaenia could be used as a simple and cost-effective biomarker to assess renal prognosis at AAV-RI diagnosis.
在自身免疫性疾病中,常观察到淋巴细胞减少症,且其与疾病活动度或预后相关。然而,在抗中性粒细胞胞质抗体(ANCA)相关性血管炎(AAV)中,仅有少数小规模研究针对这一问题。目前的研究尚未聚焦于伴有肾脏受累的 AAV(AAV-RI)。因此,本研究旨在分析大量 AAV-RI 患者的淋巴细胞计数与结局之间的关系。
我们使用了缅因州-安茹 AAV 登记处,该登记处回顾性地收集了自 2000 年 1 月以来在法国四个肾病中心连续确诊的 AAV 患者的数据。我们分析了 AAV-RI 患者的诊断时的临床、生物学和组织学数据。分析了终末期肾病(ESKD)的危险因素。还评估了无事件生存情况。
在纳入的 145 例患者中,诊断时存在淋巴细胞减少症的患者基线时肾功能较差[eGFR 为 13 比 26mL/min;P=0.002],更有可能需要肾脏替代治疗(51%比 25%;P=0.003)。淋巴细胞减少症与组织学病变相关,尤其是与硬化性肾小球的百分比相关(P=0.0027)。淋巴细胞减少症患者的 ESKD 无事件生存率较低(P<0.0001)。在多变量 Cox 分析中,淋巴细胞减少症是 ESKD 的独立危险因素[风险比 4.47(95%置信区间 2.06-9.72),P<0.001]。
淋巴细胞减少症与 AAV 肾小球肾炎的严重程度相关,可预测肾脏不良结局。在这种情况下,淋巴细胞减少症可作为一种简单且经济有效的生物标志物,用于评估 AAV-RI 诊断时的肾脏预后。